Related Experiment Video

Updated: Aug 13, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Meloxicam inhibits the growth of non-small cell lung cancer

Y Tsubouchi1, S Mukai, Y Kawahito

  • 1First Department of Internal Medicine, Kyoto Prefectural University of Medicine, Japan.

Anticancer Research
|November 4, 2000
PubMed

Insights

Meloxicam, a cyclooxygenase-2 (COX-2) inhibitor, effectively reduced the growth of non-small cell lung cancer (NSCLC) cells. This suggests COX-2 plays a role in NSCLC, and meloxicam may be a potential therapeutic agent.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Cyclooxygenase (COX)-2 is implicated in carcinogenesis.
  • Meloxicam is a preferential COX-2 inhibitor with known effects on colorectal cancer cells.

Purpose of the Study:

  • To investigate the effects of meloxicam on lung cancer cell growth.
  • To determine the expression of COX-1 and COX-2 in lung cancer cell lines.

Main Methods:

  • Reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blot analysis were used to assess COX expression.
  • MTT assays and prostaglandin E2 enzyme immunoassays evaluated cell growth and PGE2 production.

Main Results:

  • COX-2 was expressed in non-small cell lung cancer (NSCLC) cell lines (A549, PC14), but not in small cell lung cancer (SCLC) cells (H841).
  • Meloxicam inhibited the growth and prostaglandin E2 production in A549 and PC14 cells, but not in H841 cells.

Conclusions:

  • COX-2 appears to be involved in the pathogenesis and progression of NSCLC.
  • Meloxicam demonstrates potential as a therapeutic agent for NSCLC treatment.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression07:53

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Published on: March 17, 2020

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...